Biopharma needs a biggie to avoid a down deal year
M&A picked up in the third quarter but overall 2021 has been quiet on the takeover front.
World Lung 2021 – Zepzelca salvages pride from the Atlantis wreckage
Full data from the trial position the Pharmamar/Jazz small-cell lung cancer drug to remain safely on the US market.
World Lung 2021 preview – China challenges and tremelimumab rises
The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.
Marinus pushes on despite mid-stage doubts
The group’s determination to conquer another rare epilepsy, tuberous sclerosis complex, looks questionable.
Go or no go? August FDA decisions for Axsome, Sanofi and Merck
Axsome and Sanofi face FDA verdicts in depression and Pompe disease respectively, while a Keytruda combo ups the ante in kidney cancer.
Quiet times return for biopharma takeouts
The first quarter of 2021 saw fewer deals than any in recent memory.
